title: Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.
authors.affiliation: Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
authors.forename: Hussein
authors.initials: H
authors.lastname: Chalhoub
authors.affiliation: CF & Airways Microbiology Research Group, Queen's University Belfast, Belfast, UK.
authors.forename: Michael
authors.initials: M
authors.lastname: Tunney
authors.affiliation: CF & Airways Microbiology Research Group, Queen's University Belfast, Belfast, UK.
authors.forename: J Stuart
authors.initials: JS
authors.lastname: Elborn
authors.affiliation: Unité des maladies infectieuses, Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium.
authors.forename: Anne
authors.initials: A
authors.lastname: Vergison
authors.affiliation: Laboratoire de microbiologie, Hôpital Erasme, Brussels, Belgium.
authors.forename: Olivier
authors.initials: O
authors.lastname: Denis
authors.affiliation: Laboratoire de bactériologie, Hôpital Jean Minjoz, Besançon, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Plésiat
authors.affiliation: Medical Microbiology, University Hospital Münster, Münster, Germany.
authors.forename: Barbara C
authors.initials: BC
authors.lastname: Kahl
authors.affiliation: Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
authors.forename: Françoise
authors.initials: F
authors.lastname: Van Bambeke
authors.affiliation: Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium tulkens@facm.ucl.ac.be.
authors.forename: Paul M
authors.initials: PM
authors.lastname: Tulkens
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D053961:Azabicyclo Compounds / Q000494:pharmacology*; D002442:Ceftazidime / Q000494:pharmacology*; D003550:Cystic Fibrosis / Q000150:complications; D006801:Humans; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D018440:beta-Lactam Resistance / Q000187:drug effects*; D065093:beta-Lactamase Inhibitors / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; D065093:beta-Lactamase Inhibitors; C543519:avibactam; D002442:Ceftazidime
keywords: ESBLs; P. aeruginosa; carbapenemases; extended-spectrum β-lactamases; β-lactamase inhibition